Michael Jorrin, "Doc Gumshoe"

Author Bio

Michael Jorrin,
I have been a medical writer for about 25 years; before that I was a documentary film maker, and some of my films were about medical subjects. I am not a physician, but I have a pretty good scientific background. I wouldn’t dream of recommending any kind of treatment to anyone, and I cannot give medical advice. However, I understand the medical literature and the data and evidence behind it, and I have an inquiring and skeptical turn of mind. I scrutinize and question and, sometimes, challenge the positions of some of the established health-care organizations as well as the marketers of health information. Eternal vigilance is a small price to pay for health. — Michael Jorrin (aka DocGumshoe) Michael Jorrin is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

What’s New this Summer?

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

Bulletins from the Cardiac Front

[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month.  He does not typically write specifically about investments, but does write about publicly traded companies and their drugs, and has agreed to our trading […]

Antibiotic Resistance: What’s Happening?

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

The Miracle Cures Keep Coming 

[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]

End of Winter Miscellany

[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]

Responses to Recent Comments

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

Thanksgiving Leftovers and Short Takes

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

Supplements and Drugs: the Feud Redux

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

Recent Author Comments

On What’s New this Summer?
From what I have read, Genentech is only now launching a Phase 1 study in their DLK inhibitor, GDC-0134. I have the utmost respect for Genentech & my fingers are crossed as well - not only for my fellow humans, but for myself as well. Who knows wha[...]
On What’s New this Summer?
Thanks for the comment, Nick. The Phase 3 results have not been published yet, but Northwest Bio has been putting out partial results on some patients who were not included in the Phase 3 study. These appear to be promising, but so far it's anecdotal. [...]
On Hodge's "New FDA Mandate Sends This Device Into EVERY Restaurant in America"
Unless this outfit has a miraculous new method of distinguishing pathogens from the myriad harmless organisms that abound in our food and indeed in the environment, it's going nowhere. Each infectious organism has its own specific sneaky method of doing[...]
On Responses to Comments and a Proposed Study of Alcoholic Beverages
A dry cough is a common lisinopril side effect. Physicians tend to stay away from it in patients who have respiratory ailments like asthma. Fortunately there are lots of antihypertensives that work just fine.[...]
On Responses to Comments and a Proposed Study of Alcoholic Beverages
Quick answer - I agree with the philosopher Benedict Spinoza who though that there was life in everything in the universe - not just animals and plants. What is life if not divinity?[...]
On Responses to Comments and a Proposed Study of Alcoholic Beverages
Many, many thanks to Dr KSS for his comments about the hepatic effects of alcohol in women!!![...]
On Population and Health: Not Just Our Own Health, But the Health of the Planet!
Thanks all for the interesting and intelligent comments. I did not mean for my piece to sound overly pessimistic nor yet too optimistic, which is my usual foible - my mother, now looking at me with her narrowed eyes from her vantage point in the Above, i[...]
On Population and Health: Not Just Our Own Health, But the Health of the Planet!
See my reply to Alpha 2 above. Best to all, Michael Jorrin aka Doc Gumshoe[...]
On Population and Health: Not Just Our Own Health, But the Health of the Planet!
I mentioned the migrants who reached Lampedusa in the hopes of getting a foothold in the EU - almost all "economic migrants." In a sense, they too are refugees, fleeing from extreme poverty and starvation. It's hard to draw a clear line.[...]
On Friday File Hodgepodge: India, Gold and Stop Losses
Have a terrific time! Will you be reporting on single malts? Best, MJ[...]
On What's Dave Lashmet's "Biggest Ever Breakthrough for treating Alzheimer's Disease?"
I discussed aducanumab & Biogen Idec back in 2015 after the Phase Ib trial results. What was particularly positive is that the clearing of the amyloid was linked with an improvement in cognition scores. But then another trial showed no efficacy at [...]
On Examining the "One Device to End All Disease... And It Costs Less Than $50" ad from Radical Technology Profits
These tiny electronic devices may be able to detect signs of lots of diseases, but preventing & ending those diseases is another matter. To that I say, fat chance! But that doesn't mean they won't make a lot of money. Good luck, best, Michael Jor[...]
On Here We Go Again! Another Plot to Suppress Life-Saving Cures!
I've written about Parkinsonism, but not for Doc Gumshoe - not sure my piece would work in this context. Good luck to your wife! I'll look at what I wrote previously & check whether it's still up to date. Best, MJ[...]
On Here We Go Again! Another Plot to Suppress Life-Saving Cures!
Thanks very much - I'll check into nattokinase. It fits with the Academy's "Kinase N4" moniker. Best to all, Michael Jorrin (aka Doc Gumshoe)[...]
On Here We Go Again! Another Plot to Suppress Life-Saving Cures!
Thank you Indimod for the clarification, I have worked with investigators who considered PLOS in cases where other journals turned them down. In the cases of the specific paper I cited, I doubt whether those investigators would have made other options [...]
On Here We Go Again! Another Plot to Suppress Life-Saving Cures!
PLOS ONE claims to be peer-reviewed. What this amounts to is that the editorial board reads the submission and might - just might! - consult an outside expert. They publish a huge number of papers per day; from what I have learned, nothing gets rejected[...]
On Here We Go Again! Another Plot to Suppress Life-Saving Cures!
I don't think you read my piece.[...]
On Bulletins from the Cardiac Front
For a discussion of the difference between absolute and relative risk, may I refer you to the Doc Gumshoe piece from 2014 entitled "HRT: From Panacea to Anathema (and Back?). I noted that the difference in absolute and relative risks in the Women's Healt[...]
On Bulletins from the Cardiac Front
The TKR was for my left knee, the right knee having been swapped two years ago. The right knee epic was described in detail in a blog on May 1st, 2015, which you could find in the archive. With my left knee, I was in residential rehab for about a week [...]
On Bulletins from the Cardiac Front
The high-sensitivity cardiac troponin test (TnT) is indeed more sensitive than CK-MB, which is the creatine kinase subtype that indicates heart damage. The new improved TnT test may not be yet available in the US. Neither CK-MB nor the TnT test can rel[...]

This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.